ArticleJAMA network open2022
Comparison of Substance Use Disorder Diagnosis Rates From Electronic Health Record Data With Substance Use Disorder Prevalence Rates Reported in Surveys Across Sociodemographic Groups in the Veterans Health Administration.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.
- An Evidence Map of the Women Veterans' Health Literature, 2016 to 2023: A Systematic Review.JAMA network open · 2025Pooled it
- Comparison of statewide substance use disorder prevalence estimates from survey data vs electronic health record data.Drug and alcohol dependence · 2026Article
- Implementation of an opioid use disorder (OUD) machine-learning phenotype in real-time for the ADAPT clinical trial.PLOS digital health · 2026Article
- Integrated behavioral care in general hepatology increases alcohol use disorder treatment in veterans.Hepatology communications · 2026Article
- Association Between Mental Illness and Risk of Severe Maternal Morbidity in Pregnant Veterans.Obstetrics and gynecology · 2026Article
- Prevalence of Substance Use Disorders Across Five Community Health Centers in Boston, Massachusetts.Journal of general internal medicine · 2026Article
- Alcohol Use Disorder Diagnoses and HIV Preexposure Prophylaxis Adherence and Continuation: a Retrospective Cohort Study.Journal of general internal medicine · 2026Article
- Rates of Diagnosis and Treatment for Alcohol Use Disorder Among All of Us Participants with Unhealthy Alcohol Use.Journal of general internal medicine · 2026Article
- Daily web survey data collection of time-varying cannabis use motives and contexts, with implications for adaptive interventions: A pilot study.Drug and alcohol dependence · 2026Article
- Trends in stroke mortality among individuals with documented substance use: demographic and geographic disparities in U.S. adults, 1999-2023: a comparative cross-sectional study.Annals of medicine and surgery (2012) · 2026Article
- Connected Care: Challenges and Potential of Digital Interventions in Substance Use Disorder - a Narrative Review.Substance abuse and rehabilitation · 2026Review
- Moral injury and substance use among Veterans: Opportunities and challenges in rural areas.Journal of military, veteran and family health · 2025Article
- Examining Removal of Federal Waiver Restrictions to Prescribing Buprenorphine in Primary Care.Journal of the American Board of Family Medicine : JABFM · 2025Article
- Identifying Factors Associated With HIV Viral Suppression and Health Care Outcomes in the Florida Cohort Study Wave 3: Protocol for a Prospective Cohort Study.JMIR research protocols · 2025Article
- Prevalence of maternal substance use problems during pregnancy and the first 2 years of life: a whole-population birth cohort of 970 470 Australian children born 2008-2017.Journal of epidemiology and community health · 2025Article
- Trends in Prevalence and Correlates of Alcohol Use Disorder Diagnoses Among US Adult Cancer Survivors: Serial Cross-Sectional Analysis.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Variations in documentation of alcohol use disorder (AUD) diagnoses across race, ethnicity, and sex in a health system that assesses AUD symptoms as part of routine primary care.Journal of substance use and addiction treatment · 2025Article
- Improving diagnosis-based quality measures: an application of machine learning to the prediction of substance use disorder among outpatients.BMJ open quality · 2025Article
- Hospital Security Searches Among Patients With Substance-Related Encounters.JAMA network open · 2025Article
- Clinician Prescribing Practices Involving Medications for Alcohol Use Disorder.American journal of preventive medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
Importance: Substance use disorders (SUDs) are major contributors to morbidity and mortality globally, but they are often underrecognized and underdiagnosed, particularly in some sociodemographic subgroups. Understanding the extent to which clinical diagnoses underestimate these conditions within subgroups is imperative to achieving equitable treatment, regardless of race, ethnicity, gender, or age, and to informing and improving performance monitoring. Objective: To compare clinically documented diagnosis rates of alcohol use disorder (AUD), drug use disorder (DUD), and total SUD (AUD and/or DUD) with the prevalence of these disorders as reported in surveys-based on structured, validated diagnostic assessments-across demographic subgroups. Design, Setting, and Participants: A telephone-based survey was conducted from January 8, 2018, to April 30, 2019, among 5995 Veterans Health Administration (VHA) outpatients who were randomly sampled from 30 VHA facilities and were 18 years of age or older, could complete the survey in English, and had a valid address and telephone number. Survey data were linked to electronic health record (EHR) data for all participants. Statistical analysis was performed between January 29, 2020, and April 20, 2021. Exposures: Demographic subgroups based on self-report: gender (male or female), age (18-34, 35-49, 50-64, 65-74, and ≥75 years), and race and ethnicity (Black non-Hispanic, Hispanic, multiracial, other [Asian or Asian-American, American Indian or Alaskan Native, Native Hawaiian or Pacific Islander, and any other race endorsed by the participant], and White non-Hispanic). Main Outcomes and Measures: Survey-based prevalence rates of AUD, DUD, and SUD were assessed using the Mini International Neuropsychiatric Interview, version 7.0, the only validated instrument available at study outset that measured Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) criteria for past 12-month diagnoses. Clinically documented diagnosis rates were measured using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision diagnoses from VHA EHR data. Analyses compared survey-based prevalence rates of AUD, DUD, and SUD with diagnosis rates using sensitivity and specificity and difference-in-difference analysis. All analyses were weighted with survey weights to account for nonresponse. Results: Of 5995 participants, 4115 (68.6%) were White non-Hispanic, and 5429 (91.1%) were male; the mean (SD) age was 61.5 (15.3) years. The survey-based prevalence rates of AUD, DUD, and SUD were higher than the diagnosis rates among all patients (AUD, 608 [10.1%] vs 360 [6.0%]; DUD, 282 [4.7%] vs 275 [4.6%]; SUD, 768 [12.8%] vs 515 [8.6%]). Survey-based prevalence rates of AUD and SUD exceeded the diagnosis rates in every demographic subgroup. Gaps between diagnosis rates and survey-based prevalence rates for AUD and SUD were largest among patients aged 18 to 34 years (AUD diagnosis rate, 27 [6.9%; 95% CI, 4.8%-9.9%] vs AUD prevalence rate, 88 [22.4%; 95% CI, 17.3%-28.5%]; SUD diagnosis rate, 41 [10.5%; 95% CI, 8.1%-13.4%] vs SUD prevalence rate, 109 [27.7%; 95% CI, 22.6%-33.3%]) and Hispanic and Latinx patients (AUD diagnosis rate, 31 [7.6%; 95% CI, 5.3%-10.8%] vs AUD prevalence rate, 72 [17.7%; 95% CI, 14.0%-22.1%]; and SUD diagnosis rate, 48 [11.7%; 95% CI, 7.9%-16.9%] vs SUD prevalence rate, 88 [21.6%; 95% CI, 18.0%-25.8%]). For DUD, only patients aged 18 to 34 years had a true prevalence rate that significantly exceeded the diagnosis rate (diagnosis rate, 21 [5.4%; 95% CI, 3.7%-7.8%] vs prevalence rate, 40 [10.1%; 95% CI, 7.2%-14.0%]). Conclusions and Relevance: The results of this survey study suggest that existing diagnostic procedures and tools are insufficient to capture SUD prevalence rates, particularly among younger patients and Hispanic and Latinx patients. Clinics and health systems should implement standardized SUD assessments to ensure the provision of equitable care and the optimal identification of underlying conditions for performance monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.